Recent Updates
Recently added Catalysts

HTC-867

Phase 1

Schizophrenia | Small molecule | Psychiatry |Pfizer, Inc.|Last Updated: Dec 29, 2010

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment56
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01268124Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese SubjectsPHASE1 COMPLETED 56Dec 1, 2008Apr 1, 2009Dec 29, 2010 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety will be measured by vitals signs, labs and electrocardiograms (ECG's).
7 months
Secondary Endpoints
Pharmacokinetics.
7 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
TreatmentEXPERIMENTAL -
Interventions
NameTypeDescription
HTC-867DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 45 Years
SexMALE
Healthy VolunteersYes

Inclusion: 1. Men aged 20 to 45 years inclusive at screening. Sexually active men must agree to use a medically acceptable form of contraception during the study and continue it for 12 weeks after test article administration. 2. Body mass index (BMI) in the range of 17.6 to 26.4 kg/m2 and body weig...

Unlock Eligibility Criteria